. Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial. Lancet. 2025-06-21; doi: 10.1016/S0140-6736(25)01040-2. nihFormattedCitation: Olawaiye AB, Gladieff L, O'Malley DM, Kim JW, Garbaos G, Salutari V, Gilbert L, Mileshkin L, Devaux A, Hopp E, Lee YJ, Oaknin A, Scaranti M, Kim BG, Colombo N, McCollum ME, Diakos C, Clamp A, Leiser AL, Balázs B, Monk BJ, Scandurra G, McClung E, Kaczmarek E, Slomovitz B, De La Cueva H, de Carvalho Calabrich AF, Cassani C, You B, Van Gorp T, Churruca C, Caruso G, Nicum S, Bagaméri A, Artioli G, Bodnar L, Kang S, Vergote I, Kesner-Hays A, Pashova HI, Pai SG, Tudor IC, Jubb AM, Lorusso D. Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial. Lancet. 2025;.. PubMed PMID: 40473448.
. Lessons Learned About Acute and Late Toxicity After Two Decades of Experience With Pancreatic SBRT. J Natl Compr Canc Netw. 2025-06-11;1-6. doi: 10.6004/jnccn.2025.7013. nihFormattedCitation: Ellsworth SG, Abdelhakiem M, Elgohari B, Mohammed M, Shogan J, Vera A, Burton SA, Olson AC, Lee KKW, Paniccia A, Zhang JY, Lotze MT, Zureikat AH. Lessons Learned About Acute and Late Toxicity After Two Decades of Experience With Pancreatic SBRT. J Natl Compr Canc Netw. 2025;:1-6.. PubMed PMID: 40505682.
. Overdiagnosis, competing morbidity and tumour biology in older women with breast cancer: building a case for active monitoring. Nat Rev Clin Oncol. 2025-06-09; doi: 10.1038/s41571-025-01040-y. nihFormattedCitation: Carleton N, McAuliffe PF. Overdiagnosis, competing morbidity and tumour biology in older women with breast cancer: building a case for active monitoring. Nat Rev Clin Oncol. 2025;.. PubMed PMID: 40490477.
. The intestinal functions of PXR and CAR. Pharmacol Res. 2025-06-01;107779. doi: 10.1016/j.phrs.2025.107779. nihFormattedCitation: Feng Y, Kim JW, Xie W. The intestinal functions of PXR and CAR. Pharmacol Res. 2025;:107779.. PubMed PMID: 40378938.
. Integrative characterization of MYC RNA-binding function. Cell Genom. 2025-05-13;100878. doi: 10.1016/j.xgen.2025.100878. nihFormattedCitation: Li S, Wang Z, Wang X, Wang Y, Pattarayan D, Zhang Y, Nguyen P, Bhuniya A, Chen Y, Huang H, Huang Y, Wang L, Wang J, Li S, Zhang M, Liu Y, Lee N, Yang D. Integrative characterization of MYC RNA-binding function. Cell Genom. 2025;:100878.. PubMed PMID: 40378850.
. Breast Tumor-Bed Biopsy for Pathological Complete Response Prediction: The NRG-BR005 Nonrandomized Clinical Trial. JAMA Surg. 2025-05-07; doi: 10.1001/jamasurg.2025.1072. nihFormattedCitation: Basik M, Cecchini RS, De Los Santos JF, Umphrey HR, Julian TB, Mamounas EP, White JR, Lucas PC, Balanoff CR, Tan AR, Weber JJ, Edmonson DA, Brown-Glaberman UA, Diego EJ, Teshome M, Matsen CB, Seaward SA, Wapnir IL, Wagner JL, Tjoe JA, Thompson AM, Wolmark N. Breast Tumor-Bed Biopsy for Pathological Complete Response Prediction: The NRG-BR005 Nonrandomized Clinical Trial. JAMA Surg. 2025;. PMCID: PMC12060017.. PubMed PMID: 40332918; PMCID: PMC12060017.
. Rational development of gemcitabine-based nanoplatform for targeting SERPINB9/Granzyme B axis to overcome chemo-immune-resistance. Nat Commun. 2025-05-05;16(1):4176. doi: 10.1038/s41467-025-59490-y. nihFormattedCitation: Huang H, Mu Y, Huang Y, Ji B, Wang Y, Chen CY, Chen Y, Luo Z, Li S, Zhang Z, Wang L, Conway JF, Yang D, Wang J, Sun J, Li S. Rational development of gemcitabine-based nanoplatform for targeting SERPINB9/Granzyme B axis to overcome chemo-immune-resistance. Nat Commun. 2025;16(1):4176. PMCID: PMC12053578.. PubMed PMID: 40325025; PMCID: PMC12053578.
. Heme-thiolate monooxygenase cytochrome P450 1B1, an old dog with many new tricks. Pharmacol Rev. 2025-05-01;77(3):100045. doi: 10.1016/j.pharmr.2025.100045. nihFormattedCitation: Kim JW, Tung HC, Yang B, Pant R, Guan X, Feng Y, Xie W. Heme-thiolate monooxygenase cytochrome P450 1B1, an old dog with many new tricks. Pharmacol Rev. 2025;77(3):100045.. PubMed PMID: 40054133.
. Optogenetics with Atomic Precision─A Comprehensive Review of Optical Control of Protein Function through Genetic Code Expansion. Chem Rev. 2025-02-26; doi: 10.1021/acs.chemrev.4c00224. nihFormattedCitation: Charette M, Rosenblum C, Shade O, Deiters A. Optogenetics with Atomic Precision─A Comprehensive Review of Optical Control of Protein Function through Genetic Code Expansion. Chem Rev. 2025;. PMCID: PMC11869211.. PubMed PMID: 39928721; PMCID: PMC11869211.
. Advanced hierarchical computational modeling-based rational development of platinum (II) nanocomplex to improve lung cancer therapy. Adv Funct Mater. 2025-02-12;35(7): doi: 10.1002/adfm.202411334. nihFormattedCitation: Huang H, Ji B, Huang Y, Li S, Luo Z, Chen S, Li S, Chen Y, Bain DJ, Sun J, Yang D, Burns TF, Wang J, Li S. Advanced hierarchical computational modeling-based rational development of platinum (II) nanocomplex to improve lung cancer therapy. Adv Funct Mater. 2025;35(7). PMCID: PMC12124824.. PubMed PMID: 40452781; PMCID: PMC12124824.
. Emerging targets in gastric and pancreatic cancer: Focus on Claudin 18.2. Cancer Lett. 2024-12-03;217362. doi: 10.1016/j.canlet.2024.217362. nihFormattedCitation: Tojjari A, Idrissi YA, Saeed A. Emerging targets in gastric and pancreatic cancer: Focus on Claudin 18.2. Cancer Lett. 2024;:217362.. PubMed PMID: 39637967.
. Delivery of PARP inhibitors through 2HG-incorporated liposomes for synergistically targeting DNA repair in cancer. Cancer Lett. 2024-11-01;217268. doi: 10.1016/j.canlet.2024.217268. nihFormattedCitation: Luo Z, Huang Y, Chen S, Zhang B, Huang H, Dabiri S, Chen Y, Zhang A, Andreas AR, Li S. Delivery of PARP inhibitors through 2HG-incorporated liposomes for synergistically targeting DNA repair in cancer. Cancer Lett. 2024;:217268.. PubMed PMID: 39321912.
. Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial. J Clin Oncol. 2024-10-20;JCO2301995. doi: 10.1200/JCO.23.01995. nihFormattedCitation: Rastogi P, Bandos H, Lucas PC, van 't Veer LJ, Wei JJ, Geyer CE Jr, Fehrenbacher L, Chia SKL, Brufsky AM, Walshe JM, Soori GS, Dakhil SR, Paik S, Swain SM, Menicucci AR, Audeh MW, Wolmark N, Mamounas EP. Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial. J Clin Oncol. 2024;:JCO2301995. PMCID: PMC11469649.. PubMed PMID: 39047219; PMCID: PMC11469649.
. Electronic Health Record-Based Nudge Intervention and Axillary Surgery in Older Women With Breast Cancer: A Nonrandomized Controlled Trial. JAMA Surg. 2024-10-01; doi: 10.1001/jamasurg.2024.2407. nihFormattedCitation: Carleton N, Radomski TR, Li D, Zou J, Harris J, Hamm M, Wang Z, Saadawi G, Fischer GS, Arnold J, Cowher MS, Lupinacci K, Sabih Q, Steiman J, Johnson RR, Soran A, Diego EJ, Oesterreich S, Tseng G, Lee AV, McAuliffe PF. Electronic Health Record-Based Nudge Intervention and Axillary Surgery in Older Women With Breast Cancer: A Nonrandomized Controlled Trial. JAMA Surg. 2024;. PMCID: PMC11255976.. PubMed PMID: 39018053; PMCID: PMC11255976.
. Inhibition of heme-thiolate monooxygenase CYP1B1 prevents hepatic stellate cell activation and liver fibrosis by accumulating trehalose. Sci Transl Med. 2024-09-25;16(766):eadk8446. doi: 10.1126/scitranslmed.adk8446. nihFormattedCitation: Tung HC, Kim JW, Zhu J, Li S, Yan J, Liu Q, Koo I, Koshkin SA, Hao F, Zhong G, Xu M, Wang Z, Wang J, Huang Y, Xi Y, Cai X, Xu P, Ren S, Higashiyama T, Gonzalez FJ, Li S, Isoherranen N, Yang D, Ma X, Patterson AD, Xie W. Inhibition of heme-thiolate monooxygenase CYP1B1 prevents hepatic stellate cell activation and liver fibrosis by accumulating trehalose. Sci Transl Med. 2024;16(766):eadk8446. PMCID: PMC12084873.. PubMed PMID: 39321267; PMCID: PMC12084873.
. Classifying glioma via liquid biopsy--progress towards an unmet clinical need. Clin Cancer Res. 2024-07-15; doi: 10.1158/1078-0432.CCR-24-0423. nihFormattedCitation: Abdullah KG. Classifying glioma via liquid biopsy--progress towards an unmet clinical need. Clin Cancer Res. 2024;.. PubMed PMID: 38652677.
. Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810. J Clin Oncol. 2024-06-10;42(17):2061-2070. doi: 10.1200/JCO.23.01544. nihFormattedCitation: Appleman LJ, Kim SE, Harris WB, Pal SK, Pins MR, Kolesar J, Agarwal N, Parikh RA, Vaena DA, Ryan CW, Hashmi M, Costello BA, Cella D, Dutcher JP, DiPaola RS, Haas NB, Wagner LI, Carducci MA. Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810. J Clin Oncol. 2024;42(17):2061-2070. PMCID: PMC11514296.. PubMed PMID: 38531002; PMCID: PMC11514296.
. Rhodium(I)-Catalyzed Annulation of Bicyclo[1.1.0]butyl-Substituted Dihydroquinolines and Dihydropyridines. J Am Chem Soc. 2024-06-05; doi: 10.1021/jacs.4c04081. nihFormattedCitation: Borgini M, Huang QN, Chen PP, Geib SJ, Houk KN, Wipf P. Rhodium(I)-Catalyzed Annulation of Bicyclo[1.1.0]butyl-Substituted Dihydroquinolines and Dihydropyridines. J Am Chem Soc. 2024;. PMCID: PMC11157536.. PubMed PMID: 38767459; PMCID: PMC11157536.
. Knocking down of Xkr8 enhances chemotherapy efficacy through modulating tumor immune microenvironment. J Control Release. 2024-06-01; doi: 10.1016/j.jconrel.2024.04.041. nihFormattedCitation: Chen Y, Chen CY, Huang H, Luo Z, Mu Y, Li S, Li S. Knocking down of Xkr8 enhances chemotherapy efficacy through modulating tumor immune microenvironment. J Control Release. 2024;. PMCID: PMC11186464.. PubMed PMID: 38685385; PMCID: PMC11186464.
. Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial. Clin Cancer Res. 2024-05-01; doi: 10.1158/1078-0432.CCR-23-1977. nihFormattedCitation: Mamounas EP, Bandos H, Rastogi P, Zhang Y, Treuner K, Lucas PC, Geyer CE, Fehrenbacher L, Chia SK, Brufsky AM, Walshe JM, Soori GS, Dakhil S, Paik S, Swain SM, Sgroi DC, Schnabel CA, Wolmark N. Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial. Clin Cancer Res. 2024;. PMCID: PMC11061597.. PubMed PMID: 38376912; PMCID: PMC11061597.
. Long-Term Follow-Up of the Anthracyclines in Early Breast Cancer Trials (USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 [NRG Oncology]). J Clin Oncol. 2024-04-20;JCO2301428. doi: 10.1200/JCO.23.01428. nihFormattedCitation: Geyer CE Jr, Blum JL, Yothers G, Asmar L, Flynn PJ, Robert NJ, Hopkins JO, O'Shaughnessy JA, Rastogi P, Puhalla SL, Hilton CJ, Dang CT, Gómez HL, Vukelja SJ, Lyss AP, Paul D, Brufsky AM, Colangelo LH, Swain SM, Mamounas EP, Wolmark N. Long-Term Follow-Up of the Anthracyclines in Early Breast Cancer Trials (USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 [NRG Oncology]). J Clin Oncol. 2024;:JCO2301428. PMCID: PMC11095853.. PubMed PMID: 38335467; PMCID: PMC11095853.
. Impact of the 2021 CKD-EPI equation on anticancer pharmacotherapy in black and non-black cancer patients. Cancer Lett. 2024-04-01;216679. doi: 10.1016/j.canlet.2024.216679. nihFormattedCitation: Butrovich MA, Qin J, Xue X, Ivy SP, Nolin TD, Beumer JH. Impact of the 2021 CKD-EPI equation on anticancer pharmacotherapy in black and non-black cancer patients. Cancer Lett. 2024;:216679. PMCID: PMC10939791.. PubMed PMID: 38307411; PMCID: PMC10939791.
. Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Ou J Clin Oncol. 2024-03-20;JCO2301994. doi: 10.1200/JCO.23.01994. nihFormattedCitation: Rastogi P, O'Shaughnessy J, Martin M, Boyle F, Cortes J, Rugo HS, Goetz MP, Hamilton EP, Huang CS, Senkus E, Tryakin A, Cicin I, Testa L, Neven P, Huober J, Shao Z, Wei R, André V, Munoz M, San Antonio B, Shahir A, Harbeck N, Johnston S. Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Ou J Clin Oncol. 2024;:JCO2301994. PMCID: PMC10950161.. PubMed PMID: 38194616; PMCID: PMC10950161.
. Knocking down of Xkr8 enhances chemotherapy efficacy through modulating tumor immune microenvironment. J Control Release. 2024-03-10; doi: 10.1016/j.jconrel.2024.03.011. nihFormattedCitation: Chen Y, Chen CY, Huang H, Luo Z, Mu Y, Li S, Li S. Knocking down of Xkr8 enhances chemotherapy efficacy through modulating tumor immune microenvironment. J Control Release. 2024;.. PubMed PMID: 38471639.
. Phase 2 study of epigenetic priming with decitabine followed by cytarabine for acute myeloid leukemia in older patients. Am J Hematol. 2024-03-01; doi: 10.1002/ajh.27212. nihFormattedCitation: Im A, Quann K, Agha M, Raptis A, Redner RL, Hou JZ, Farah R, Dorritie KA, Sehgal AR, Normolle D, Bovbjerg DH, Aggarwal N, Herman J, Lontos K, Boyiadzis M. Phase 2 study of epigenetic priming with decitabine followed by cytarabine for acute myeloid leukemia in older patients. Am J Hematol. 2024;. PMCID: PMC11552450.. PubMed PMID: 38258329; PMCID: PMC11552450.
. Sulfation of chondroitin and bile acids converges to antagonize Wnt/β-catenin signaling and inhibit APC deficiency-induced gut tumorigenesis. Acta Pharm Sin B. 2024-03-01;14(3):1241-1256. doi: 10.1016/j.apsb.2023.12.006. nihFormattedCitation: Xu P, Xi Y, Kim JW, Zhu J, Zhang M, Xu M, Ren S, Yang D, Ma X, Xie W. Sulfation of chondroitin and bile acids converges to antagonize Wnt/β-catenin signaling and inhibit APC deficiency-induced gut tumorigenesis. Acta Pharm Sin B. 2024;14(3):1241-1256. PMCID: PMC10935170.. PubMed PMID: 38487006; PMCID: PMC10935170.
. Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort. Nat Commun. 2024-02-20;15(1):1533. doi: 10.1038/s41467-024-45960-2. nihFormattedCitation: Saeed A, Park R, Pathak H, Al-Bzour AN, Dai J, Phadnis M, Al-Rajabi R, Kasi A, Baranda J, Sun W, Williamson S, Chiu YC, Osmanbeyoglu HU, Madan R, Abushukair H, Mulvaney K, Godwin AK, Saeed A. Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort. Nat Commun. 2024;15(1):1533. PMCID: PMC10879200.. PubMed PMID: 38378868; PMCID: PMC10879200.
. SCLC Classification by Platinum Sensitivity in the Era of Immunotherapy: Mere Relic or a Valuable Treasure to Keep? J Thorac Oncol. 2024-02-01;19(2):193-195. doi: 10.1016/j.jtho.2023.11.022. nihFormattedCitation: Owonikoko TK. SCLC Classification by Platinum Sensitivity in the Era of Immunotherapy: Mere Relic or a Valuable Treasure to Keep? J Thorac Oncol. 2024;19(2):193-195.. PubMed PMID: 38325978.
. Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study. Cancer Discov. 2024-01-12;OF1-OF14. doi: 10.1158/2159-8290.CD-23-0964. nihFormattedCitation: Kelly WK, Danila DC, Lin CC, Lee JL, Matsubara N, Ward PJ, Armstrong AJ, Pook D, Kim M, Dorff TB, Fischer S, Lin YC, Horvath LG, Sumey C, Yang Z, Jurida G, Smith KM, Connarn JN, Penny HL, Stieglmaier J, Appleman LJ. Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study. Cancer Discov. 2024;:OF1-OF14. PMCID: PMC10784743.. PubMed PMID: 37861461; PMCID: PMC10784743.
. Project Confirm: Accelerated Drug Approvals for CML-Letter. Clin Cancer Res. 2024-01-05;30(1):235-236. doi: 10.1158/1078-0432.CCR-23-2630. nihFormattedCitation: Beumer JH, Salamone SJ. Project Confirm: Accelerated Drug Approvals for CML-Letter. Clin Cancer Res. 2024;30(1):235-236. PMCID: PMC10783536.. PubMed PMID: 38178775; PMCID: PMC10783536.
. Inhibition of iRhom1 by CD44-targeting nanocarrier for improved cancer immunochemotherapy. Nat Commun. 2024-01-04;15(1):255. doi: 10.1038/s41467-023-44572-6. nihFormattedCitation: Luo Z, Huang Y, Batra N, Chen Y, Huang H, Wang Y, Zhang Z, Li S, Chen CY, Wang Z, Sun J, Wang QJ, Yang D, Lu B, Conway JF, Li LY, Yu AM, Li S. Inhibition of iRhom1 by CD44-targeting nanocarrier for improved cancer immunochemotherapy. Nat Commun. 2024;15(1):255. PMCID: PMC10766965.. PubMed PMID: 38177179; PMCID: PMC10766965.
. Impact of Recombinant Granulocyte Colony-Stimulating Factor During Neoadjuvant Therapy on Outcomes of Resected Pancreatic Cancer. J Natl Compr Canc Netw. 2023-12-27;1-13. doi: 10.6004/jnccn.2023.7070. nihFormattedCitation: Murthy P, Zenati MS, AlMasri SS, DeSilva A, Singhi AD, Paniccia A, Lee KK, Simmons RL, Bahary N, Lotze MT, Zureikat AH. Impact of Recombinant Granulocyte Colony-Stimulating Factor During Neoadjuvant Therapy on Outcomes of Resected Pancreatic Cancer. J Natl Compr Canc Netw. 2023;:1-13.. PubMed PMID: 38150819.
. A phase II clinical trial evaluating the safety and efficacy of durvalumab as first line therapy in advanced and metastatic non-small cell lung cancer patients with Eastern Cooperative Oncology Group performance status of 2. EClinicalMedicine. 2023-12-01;66102317. doi: 10.1016/j.eclinm.2023.102317. nihFormattedCitation: Shaverdashvili K, Reyes V, Wang H, Mehta D, Marsh C, Waas JK, VanderWeele RA, Peracha SM, Liang H, Socinski MA, Gerber DE, Dowell JE, Villaruz LC. A phase II clinical trial evaluating the safety and efficacy of durvalumab as first line therapy in advanced and metastatic non-small cell lung cancer patients with Eastern Cooperative Oncology Group performance status of 2. EClinicalMedicine. 2023;66:102317. PMCID: PMC10772260.. PubMed PMID: 38192592; PMCID: PMC10772260.
. Targeting cancer metabolic pathways for improving chemotherapy and immunotherapy. Cancer Lett. 2023-10-28;216396. doi: 10.1016/j.canlet.2023.216396. nihFormattedCitation: Luo Z, Eichinger KM, Zhang A, Li S. Targeting cancer metabolic pathways for improving chemotherapy and immunotherapy. Cancer Lett. 2023;:216396. PMCID: PMC10591810.. PubMed PMID: 37739209; PMCID: PMC10591810.
. Cell Surface Labeling and Detection of Protein Tyrosine Kinase 7 via Covalent Aptamers. J Am Chem Soc. 2023-08-02;145(30):16458-16463. doi: 10.1021/jacs.3c02752. nihFormattedCitation: Albright S, Cacace M, Tivon Y, Deiters A. Cell Surface Labeling and Detection of Protein Tyrosine Kinase 7 via Covalent Aptamers. J Am Chem Soc. 2023;145(30):16458-16463. PMCID: PMC10401710.. PubMed PMID: 37473438; PMCID: PMC10401710.
. Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor-Positive Breast Cancer. J Clin Oncol. 2023-07-10;41(20):3565-3575. doi: 10.1200/JCO.22.02570. nihFormattedCitation: Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, Costantino JP, Geyer CE Jr, Wickerham DL, Wolmark N. Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor-Positive Breast Cancer. J Clin Oncol. 2023;41(20):3565-3575.. PubMed PMID: 37406456.
. Precision medicine for metastatic TNBC: the FUTURE is now. Cell Res. 2023-07-01;33(7):491-492. doi: 10.1038/s41422-023-00815-1. nihFormattedCitation: Foldi J, Geyer CE Jr. Precision medicine for metastatic TNBC: the FUTURE is now. Cell Res. 2023;33(7):491-492. PMCID: PMC10313756.. PubMed PMID: 37156878; PMCID: PMC10313756.
. Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. J Clin Oncol. 2023-06-01;41(16):2893-2903. doi: 10.1200/JCO.22.02823. nihFormattedCitation: Paz-Ares L, Champiat S, Lai WV, Izumi H, Govindan R, Boyer M, Hummel HD, Borghaei H, Johnson ML, Steeghs N, Blackhall F, Dowlati A, Reguart N, Yoshida T, He K, Gadgeel SM, Felip E, Zhang Y, Pati A, Minocha M, Mukherjee S, Goldrick A, Nagorsen D, Hashemi Sadraei N, Owonikoko TK. Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. J Clin Oncol. 2023;41(16):2893-2903. PMCID: PMC10414718.. PubMed PMID: 36689692; PMCID: PMC10414718.
. Cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies: Phase Ib CAMILLA trial results. Cell Rep Med. 2023-02-21;4(2):100916. doi: 10.1016/j.xcrm.2023.100916. nihFormattedCitation: Saeed A, Park R, Dai J, Al-Rajabi R, Kasi A, Baranda J, Williamson S, Saeed A, Ripp J, Collins Z, Mulvaney K, Shugrue M, Firth-Braun J, Godwin AK, Madan R, Phadnis M, Sun W. Cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies: Phase Ib CAMILLA trial results. Cell Rep Med. 2023;4(2):100916. PMCID: PMC9975105.. PubMed PMID: 36702123; PMCID: PMC9975105.
. Response to Neoadjuvant Targeted Therapy in Operable Head and Neck Cancer Confers Survival Benefit. Clin Cancer Res. 2023-02-16;29(4):723-730. doi: 10.1158/1078-0432.CCR-22-1768. nihFormattedCitation: Mascarella MA, Olonisakin TF, Rumde P, Vendra V, Nance MA, Kim S, Kubik MW, Sridharan SS, Ferris RL, Fenton MJ, Clayburgh DR, Ohr JP, Joyce SC, Sen M, Herman JG, Grandis JR, Zandberg DP, Duvvuri U. Response to Neoadjuvant Targeted Therapy in Operable Head and Neck Cancer Confers Survival Benefit. Clin Cancer Res. 2023;29(4):723-730. PMCID: PMC11232033.. PubMed PMID: 36595540; PMCID: PMC11232033.
. Improved antitumor activity against prostate cancer via synergistic targeting of Myc and GFAT-1. Theranostics. 2023-01-01;13(2):578-595. doi: 10.7150/thno.76614. nihFormattedCitation: Zhang Y, Li J, Huang Y, Chen Y, Luo Z, Huang H, West RE 3rd, Nolin TD, Wang Z, Li S. Improved antitumor activity against prostate cancer via synergistic targeting of Myc and GFAT-1. Theranostics. 2023;13(2):578-595. PMCID: PMC9830436.. PubMed PMID: 36632215; PMCID: PMC9830436.
. Evaluation of Adjuvant Chemotherapy Survival Outcomes Among Patients With Surgically Resected Pancreatic Carcinoma With Node-Negative Disease After Neoadjuvant Therapy. JAMA Surg. 2023-01-01;158(1):55-62. doi: 10.1001/jamasurg.2022.5696. nihFormattedCitation: Hammad AY, Hodges JC, AlMasri S, Paniccia A, Lee KK, Bahary N, Singhi AD, Ellsworth SG, Aldakkak M, Evans DB, Tsai S, Zureikat A. Evaluation of Adjuvant Chemotherapy Survival Outcomes Among Patients With Surgically Resected Pancreatic Carcinoma With Node-Negative Disease After Neoadjuvant Therapy. JAMA Surg. 2023;158(1):55-62. PMCID: PMC9685551.. PubMed PMID: 36416848; PMCID: PMC9685551.
. All Optimal Dosing Roads Lead to Therapeutic Drug Monitoring-Why Take the Slow Lane. JAMA Oncol. 2022-12-01;8(12):1733-1735. doi: 10.1001/jamaoncol.2022.4452. nihFormattedCitation: Beumer JH, Chu E, Salamone SJ. All Optimal Dosing Roads Lead to Therapeutic Drug Monitoring-Why Take the Slow Lane. JAMA Oncol. 2022;8(12):1733-1735. PMCID: PMC9772116.. PubMed PMID: 36264552; PMCID: PMC9772116.
. Are the chronological age cutoffs used in clinical oncology guidelines biologically meaningful? Nat Rev Clin Oncol. 2022-12-01;19(12):745-746. doi: 10.1038/s41571-022-00684-4. nihFormattedCitation: Carleton N, McAuliffe PF. Are the chronological age cutoffs used in clinical oncology guidelines biologically meaningful? Nat Rev Clin Oncol. 2022;19(12):745-746. PMCID: PMC9675711.. PubMed PMID: 36042383; PMCID: PMC9675711.
. HLA-A*03 and response to immune checkpoint blockade in patients with cancer. Lancet Oncol. 2022-03-01;23(3):e99. doi: 10.1016/S1470-2045(22)00086-9. nihFormattedCitation: Diamantopoulos LN, Appleman LJ. HLA-A*03 and response to immune checkpoint blockade in patients with cancer. Lancet Oncol. 2022;23(3):e99.. PubMed PMID: 35240100.
. Engineering a folic acid-decorated ultrasmall gemcitabine nanocarrier for breast cancer therapy: Dual targeting of tumor cells and tumor-associated macrophages. Acta Pharm Sin B. 2022-03-01;12(3):1148-1162. doi: 10.1016/j.apsb.2021.09.024. nihFormattedCitation: Moharil P, Wan Z, Pardeshi A, Li J, Huang H, Luo Z, Rathod S, Zhang Z, Chen Y, Zhang B, Fernandez CA, Sun J, Li S. Engineering a folic acid-decorated ultrasmall gemcitabine nanocarrier for breast cancer therapy: Dual targeting of tumor cells and tumor-associated macrophages. Acta Pharm Sin B. 2022;12(3):1148-1162. PMCID: PMC9072252.. PubMed PMID: 35530140; PMCID: PMC9072252.
. Targeting metabotropic glutamate receptor 4 for cancer immunotherapy. Sci Adv. 2021-12-10;7(50):eabj4226. doi: 10.1126/sciadv.abj4226. nihFormattedCitation: Wan Z, Sun R, Liu YW, Li S, Sun J, Li J, Zhu J, Moharil P, Zhang B, Ren P, Ren G, Zhang M, Ma X, Dai S, Yang D, Lu B, Li S. Targeting metabotropic glutamate receptor 4 for cancer immunotherapy. Sci Adv. 2021;7(50):eabj4226. PMCID: PMC8664261.. PubMed PMID: 34890233; PMCID: PMC8664261.
. Translational control of gene function through optically regulated nucleic acids. Chem Soc Rev. 2021-11-29;50(23):13253-13267. doi: 10.1039/d1cs00257k. nihFormattedCitation: Darrah KE, Deiters A. Translational control of gene function through optically regulated nucleic acids. Chem Soc Rev. 2021;50(23):13253-13267. PMCID: PMC8900068.. PubMed PMID: 34739027; PMCID: PMC8900068.
. Recurrent Human Papillomavirus-Related Head and Neck Cancer Undergoes Metabolic Reprogramming and Is Driven by Oxidative Phosphorylation. Clin Cancer Res. 2021-11-15;27(22):6250-6264. doi: 10.1158/1078-0432.CCR-20-4789. nihFormattedCitation: Vyas A, Harbison RA, Faden DL, Kubik M, Palmer D, Zhang Q, Osmanbeyoglu HU, Kiselyov K, Méndez E, Duvvuri U. Recurrent Human Papillomavirus-Related Head and Neck Cancer Undergoes Metabolic Reprogramming and Is Driven by Oxidative Phosphorylation. Clin Cancer Res. 2021;27(22):6250-6264. PMCID: PMC8611487.. PubMed PMID: 34407971; PMCID: PMC8611487.
. Small Molecule Control of Morpholino Antisense Oligonucleotide Function through Staudinger Reduction. J Am Chem Soc. 2021-11-10;143(44):18665-18671. doi: 10.1021/jacs.1c08723. nihFormattedCitation: Darrah K, Wesalo J, Lukasak B, Tsang M, Chen JK, Deiters A. Small Molecule Control of Morpholino Antisense Oligonucleotide Function through Staudinger Reduction. J Am Chem Soc. 2021;143(44):18665-18671. PMCID: PMC9014490.. PubMed PMID: 34705461; PMCID: PMC9014490.
. Ovarian function suppression as a potential mechanism of chemotherapy. EBioMedicine. 2021-08-01;70103489. doi: 10.1016/j.ebiom.2021.103489. nihFormattedCitation: Gomez Marti JL, Nasrazadani A, Brufsky AM. Ovarian function suppression as a potential mechanism of chemotherapy. EBioMedicine. 2021;70:103489. PMCID: PMC8318981.. PubMed PMID: 34280778; PMCID: PMC8318981.
. Comparison of Radiation With or Without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy: A Phase III Clinical Trial. J Clin Oncol. 2021-07-20;39(21):2367-2374. doi: 10.1200/JCO.20.02824. nihFormattedCitation: Cobleigh MA, Anderson SJ, Siziopikou KP, Arthur DW, Rabinovitch R, Julian TB, Parda DS, Seaward SA, Carter DL, Lyons JA, Dillmon MS, Magrinat GC, Kavadi VS, Zibelli AM, Tiriveedhi L, Hill ML, Melnik MK, Beriwal S, Mamounas EP, Wolmark N. Comparison of Radiation With or Without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy: A Phase III Clinical Trial. J Clin Oncol. 2021;39(21):2367-2374. PMCID: PMC8462554.. PubMed PMID: 33739848; PMCID: PMC8462554.
. Author response to Cunha et al. J Immunother Cancer. 2021-07-01;9(7): doi: 10.1136/jitc-2021-003299. nihFormattedCitation: Colen RR, Rolfo C, Ak M, Ayoub M, Ahmed S, Elshafeey N, Mamindla P, Zinn PO, Ng C, Vikram R, Bakas S, Peterson CB, Rodon Ahnert J, Subbiah V, Karp DD, Stephen B, Hajjar J, Naing A. Author response to Cunha et al. J Immunother Cancer. 2021;9(7). PMCID: PMC8317086.. PubMed PMID: 34315823; PMCID: PMC8317086.
. Intestinal Sulfation Is Essential to Protect Against Colitis and Colonic Carcinogenesis. Gastroenterology. 2021-07-01;161(1):271-286.e11. doi: 10.1053/j.gastro.2021.03.048. nihFormattedCitation: Xu P, Xi Y, Zhu J, Zhang M, Luka Z, Stolz DB, Cai X, Xie Y, Xu M, Ren S, Huang Z, Yang D, York JD, Ma X, Xie W. Intestinal Sulfation Is Essential to Protect Against Colitis and Colonic Carcinogenesis. Gastroenterology. 2021;161(1):271-286.e11. PMCID: PMC8238844.. PubMed PMID: 33819483; PMCID: PMC8238844.
. DPP4(+) exosomes in AML patients' plasma suppress proliferation of hematopoietic progenitor cells. Leukemia. 2021-07-01;35(7):1925-1932. doi: 10.1038/s41375-020-01047-7. nihFormattedCitation: Namburi S, Broxmeyer HE, Hong CS, Whiteside TL, Boyiadzis M. DPP4(+) exosomes in AML patients' plasma suppress proliferation of hematopoietic progenitor cells. Leukemia. 2021;35(7):1925-1932. PMCID: PMC10165724.. PubMed PMID: 33139859; PMCID: PMC10165724.
. Targeted Protein Degradation through Fast Optogenetic Activation and Its Application to the Control of Cell Signaling. J Am Chem Soc. 2021-06-23;143(24):9222-9229. doi: 10.1021/jacs.1c04324. nihFormattedCitation: Ryan A, Liu J, Deiters A. Targeted Protein Degradation through Fast Optogenetic Activation and Its Application to the Control of Cell Signaling. J Am Chem Soc. 2021;143(24):9222-9229.. PubMed PMID: 34121391.
. Crizotinib in Patients With MET-Amplified NSCLC. J Thorac Oncol. 2021-06-01;16(6):1017-1029. doi: 10.1016/j.jtho.2021.02.010. nihFormattedCitation: Camidge DR, Otterson GA, Clark JW, Ignatius Ou SH, Weiss J, Ades S, Shapiro GI, Socinski MA, Murphy DA, Conte U, Tang Y, Wang SC, Wilner KD, Villaruz LC. Crizotinib in Patients With MET-Amplified NSCLC. J Thorac Oncol. 2021;16(6):1017-1029.. PubMed PMID: 33676017.
. Reply to K. Hashimoto and A. Shimomura. J Clin Oncol. 2021-05-01;39(13):1507-1508. doi: 10.1200/JCO.20.03477. nihFormattedCitation: Johnston SRD, Harbeck N, Toi M, Martin M, O'Shaughnessy J, Rastogi P. Reply to K. Hashimoto and A. Shimomura. J Clin Oncol. 2021;39(13):1507-1508.. PubMed PMID: 33630658.
. Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers. J Immunother Cancer. 2021-04-01;9(4): doi: 10.1136/jitc-2020-001752. nihFormattedCitation: Colen RR, Rolfo C, Ak M, Ayoub M, Ahmed S, Elshafeey N, Mamindla P, Zinn PO, Ng C, Vikram R, Bakas S, Peterson CB, Rodon Ahnert J, Subbiah V, Karp DD, Stephen B, Hajjar J, Naing A. Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers. J Immunother Cancer. 2021;9(4). PMCID: PMC8051405.. PubMed PMID: 33849924; PMCID: PMC8051405.
. Outcomes After Sentinel Lymph Node Biopsy and Radiotherapy in Older Women With Early-Stage, Estrogen Receptor-Positive Breast Cancer. JAMA Netw Open. 2021-04-01;4(4):e216322. doi: 10.1001/jamanetworkopen.2021.6322. nihFormattedCitation: Carleton N, Zou J, Fang Y, Koscumb SE, Shah OS, Chen F, Beriwal S, Diego EJ, Brufsky AM, Oesterreich S, Shapiro SD, Ferris R, Emens LA, Tseng G, Marroquin OC, Lee AV, McAuliffe PF. Outcomes After Sentinel Lymph Node Biopsy and Radiotherapy in Older Women With Early-Stage, Estrogen Receptor-Positive Breast Cancer. JAMA Netw Open. 2021;4(4):e216322. PMCID: PMC8050744.. PubMed PMID: 33856473; PMCID: PMC8050744.
. Impact of upfront chemotherapy on overall survival in isolated myeloid sarcoma. Leukemia. 2021-04-01;35(4):1193-1196. doi: 10.1038/s41375-020-01017-z. nihFormattedCitation: Lontos K, Yabes JG, Farah RJ, Boyiadzis M. Impact of upfront chemotherapy on overall survival in isolated myeloid sarcoma. Leukemia. 2021;35(4):1193-1196.. PubMed PMID: 32814841.
. A novel immunochemotherapy based on targeting of cyclooxygenase and induction of immunogenic cell death. Biomaterials. 2021-03-01;270120708. doi: 10.1016/j.biomaterials.2021.120708. nihFormattedCitation: Huang H, Huang Y, Chen Y, Luo Z, Zhang Z, Sun R, Wan Z, Sun J, Lu B, Zhang L, Hu J, Li S. A novel immunochemotherapy based on targeting of cyclooxygenase and induction of immunogenic cell death. Biomaterials. 2021;270:120708. PMCID: PMC7910750.. PubMed PMID: 33578254; PMCID: PMC7910750.
. Tumor size-dependent abscopal effect of polydopamine-coated all-in-one nanoparticles for immunochemo-photothermal therapy of early- and late-stage metastatic cancer. Biomaterials. 2021-02-01;269120629. doi: 10.1016/j.biomaterials.2020.120629. nihFormattedCitation: Sun J, Wan Z, Xu J, Luo Z, Ren P, Zhang B, Diao D, Huang Y, Li S. Tumor size-dependent abscopal effect of polydopamine-coated all-in-one nanoparticles for immunochemo-photothermal therapy of early- and late-stage metastatic cancer. Biomaterials. 2021;269:120629. PMCID: PMC8466812.. PubMed PMID: 33387938; PMCID: PMC8466812.
. Reply to T. J. A. Dekker, D.-C. Mo et al, and A. Seidman et al. J Clin Oncol. 2021-01-20;39(3):254-255. doi: 10.1200/JCO.20.02963. nihFormattedCitation: Saura C, Oliveira M, Kim SB, Yau T, Takano T, Brufsky A. Reply to T. J. A. Dekker, D.-C. Mo et al, and A. Seidman et al. J Clin Oncol. 2021;39(3):254-255.. PubMed PMID: 33332192.
. ERINA Is an Estrogen-Responsive LncRNA That Drives Breast Cancer through the E2F1/RB1 Pathway. Cancer Res. 2020-10-15;80(20):4399-4413. doi: 10.1158/0008-5472.CAN-20-1031. nihFormattedCitation: Fang Z, Wang Y, Wang Z, Xu M, Ren S, Yang D, Hong M, Xie W. ERINA Is an Estrogen-Responsive LncRNA That Drives Breast Cancer through the E2F1/RB1 Pathway. Cancer Res. 2020;80(20):4399-4413. PMCID: PMC7572695.. PubMed PMID: 32826278; PMCID: PMC7572695.
. The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia. J Immunother Cancer. 2020-10-01;8(2): doi: 10.1136/jitc-2020-000810. nihFormattedCitation: Boyiadzis MM, Aksentijevich I, Arber DA, Barrett J, Brentjens RJ, Brufsky J, Cortes J, De Lima M, Forman SJ, Fuchs EJ, Fukas LJ, Gore SD, Litzow MR, Miller JS, Pagel JM, Waller EK, Tallman MS. The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia. J Immunother Cancer. 2020;8(2). PMCID: PMC7574947.. PubMed PMID: 33077513; PMCID: PMC7574947.
. NSABP B-41, a Randomized Neoadjuvant Trial: Genes and Signatures Associated with Pathologic Complete Response. Clin Cancer Res. 2020-08-15;26(16):4233-4241. doi: 10.1158/1078-0432.CCR-20-0152. nihFormattedCitation: Swain SM, Tang G, Brauer HA, Goerlitz DS, Lucas PC, Robidoux A, Harris BT, Bandos H, Ren Y, Geyer CE Jr, Rastogi P, Mamounas EP, Wolmark N. NSABP B-41, a Randomized Neoadjuvant Trial: Genes and Signatures Associated with Pathologic Complete Response. Clin Cancer Res. 2020;26(16):4233-4241. PMCID: PMC7724952.. PubMed PMID: 32371537; PMCID: PMC7724952.
. Immune Checkpoint Blockade in Oncogene-Driven Non-Small-Cell Lung Cancer. Drugs. 2020-06-01;80(9):883-892. doi: 10.1007/s40265-020-01320-0. nihFormattedCitation: Somasundaram A, Socinski MA, Villaruz LC. Immune Checkpoint Blockade in Oncogene-Driven Non-Small-Cell Lung Cancer. Drugs. 2020;80(9):883-892. PMCID: PMC8579493.. PubMed PMID: 32436070; PMCID: PMC8579493.
. Capivasertib inhibits a key pathway in metastatic breast cancer. Lancet Oncol. 2020-03-01;21(3):318-319. doi: 10.1016/S1470-2045(19)30857-5. nihFormattedCitation: Nasrazadani A, Brufsky AM. Capivasertib inhibits a key pathway in metastatic breast cancer. Lancet Oncol. 2020;21(3):318-319.. PubMed PMID: 32035019.
. NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2. J Clin Oncol. 2020-02-10;38(5):444-453. doi: 10.1200/JCO.19.01455. nihFormattedCitation: Fehrenbacher L, Cecchini RS, Geyer CE Jr, Rastogi P, Costantino JP, Atkins JN, Crown JP, Polikoff J, Boileau JF, Provencher L, Stokoe C, Moore TD, Robidoux A, Flynn PJ, Borges VF, Albain KS, Swain SM, Paik S, Mamounas EP, Wolmark N. NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2. J Clin Oncol. 2020;38(5):444-453. PMCID: PMC7007289.. PubMed PMID: 31821109; PMCID: PMC7007289.
. Optical Control of Small Molecule-Induced Protein Degradation. J Am Chem Soc. 2020-02-05;142(5):2193-2197. doi: 10.1021/jacs.9b12718. nihFormattedCitation: Naro Y, Darrah K, Deiters A. Optical Control of Small Molecule-Induced Protein Degradation. J Am Chem Soc. 2020;142(5):2193-2197. PMCID: PMC7229639.. PubMed PMID: 31927988; PMCID: PMC7229639.
. Sensitizing Triple Negative Breast Cancer to Tamoxifen Chemotherapy via a Redox-Responsive Vorinostat-containing Polymeric Prodrug Nanocarrier. Theranostics. 2020-01-20;10(6):2463-2478. doi: 10.7150/thno.38973. nihFormattedCitation: Ma W, Sun J, Xu J, Luo Z, Diao D, Zhang Z, Oberly PJ, Minnigh MB, Xie W, Poloyac SM, Huang Y, Li S. Sensitizing Triple Negative Breast Cancer to Tamoxifen Chemotherapy via a Redox-Responsive Vorinostat-containing Polymeric Prodrug Nanocarrier. Theranostics. 2020;10(6):2463-2478. PMCID: PMC7052901.. PubMed PMID: 32194813; PMCID: PMC7052901.
. High Loading of Hydrophobic and Hydrophilic Agents via Small Immunostimulatory Carrier for Enhanced Tumor Penetration and Combinational Therapy. Theranostics. 2020-01-01;10(3):1136-1150. doi: 10.7150/thno.38287. nihFormattedCitation: Sun J, Chen Y, Xu J, Song X, Wan Z, Du Y, Ma W, Li X, Zhang L, Li S. High Loading of Hydrophobic and Hydrophilic Agents via Small Immunostimulatory Carrier for Enhanced Tumor Penetration and Combinational Therapy. Theranostics. 2020;10(3):1136-1150. PMCID: PMC6956803.. PubMed PMID: 31938056; PMCID: PMC6956803.
. Editorial of Special Issue on Drug Metabolism and Disposition in Diseases. Acta Pharm Sin B. 2020-01-01;10(1):2. doi: 10.1016/j.apsb.2019.12.016. nihFormattedCitation: Xie W. Editorial of Special Issue on Drug Metabolism and Disposition in Diseases. Acta Pharm Sin B. 2020;10(1):2. PMCID: PMC6977160.. PubMed PMID: 31993303; PMCID: PMC6977160.
. Long-noncoding RNAs (lncRNAs) in drug metabolism and disposition, implications in cancer chemo-resistance. Acta Pharm Sin B. 2020-01-01;10(1):105-112. doi: 10.1016/j.apsb.2019.09.011. nihFormattedCitation: Wang Y, Fang Z, Hong M, Yang D, Xie W. Long-noncoding RNAs (lncRNAs) in drug metabolism and disposition, implications in cancer chemo-resistance. Acta Pharm Sin B. 2020;10(1):105-112. PMCID: PMC6976993.. PubMed PMID: 31993309; PMCID: PMC6976993.
. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet. 2019-12-14;394(10215):2155-2164. doi: 10.1016/S0140-6736(19)32514-0. nihFormattedCitation: Vicini FA, Cecchini RS, White JR, Arthur DW, Julian TB, Rabinovitch RA, Kuske RR, Ganz PA, Parda DS, Scheier MF, Winter KA, Paik S, Kuerer HM, Vallow LA, Pierce LJ, Mamounas EP, McCormick B, Costantino JP, Bear HD, Germain I, Gustafson G, Grossheim L, Petersen IA, Hudes RS, Curran WJ Jr, Bryant JL, Wolmark N. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet. 2019;394(10215):2155-2164. PMCID: PMC7199428.. PubMed PMID: 31813636; PMCID: PMC7199428.
. CDK4/6 inhibitors: taking the place of chemotherapy? Lancet Oncol. 2019-10-01;20(10):1329-1330. doi: 10.1016/S1470-2045(19)30507-8. nihFormattedCitation: Nasrazadani A, Brufsky AM. CDK4/6 inhibitors: taking the place of chemotherapy? Lancet Oncol. 2019;20(10):1329-1330.. PubMed PMID: 31494036.
. Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma Patients. Clin Cancer Res. 2019-10-01;25(19):5752-5758. doi: 10.1158/1078-0432.CCR-18-3453. nihFormattedCitation: Duvvuri U, George J, Kim S, Alvarado D, Neumeister VM, Chenna A, Gedrich R, Hawthorne T, LaVallee T, Grandis JR, Bauman JE. Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma Patients. Clin Cancer Res. 2019;25(19):5752-5758. PMCID: PMC6820348.. PubMed PMID: 31308059; PMCID: PMC6820348.
. Optical control of protein phosphatase function. Nat Commun. 2019-09-26;10(1):4384. doi: 10.1038/s41467-019-12260-z. nihFormattedCitation: Courtney TM, Deiters A. Optical control of protein phosphatase function. Nat Commun. 2019;10(1):4384. PMCID: PMC6763421.. PubMed PMID: 31558717; PMCID: PMC6763421.
. Aryl Hydrocarbon Receptor Signaling Prevents Activation of Hepatic Stellate Cells and Liver Fibrogenesis in Mice. Gastroenterology. 2019-09-01;157(3):793-806.e14. doi: 10.1053/j.gastro.2019.05.066. nihFormattedCitation: Yan J, Tung HC, Li S, Niu Y, Garbacz WG, Lu P, Bi Y, Li Y, He J, Xu M, Ren S, Monga SP, Schwabe RF, Yang D, Xie W. Aryl Hydrocarbon Receptor Signaling Prevents Activation of Hepatic Stellate Cells and Liver Fibrogenesis in Mice. Gastroenterology. 2019;157(3):793-806.e14. PMCID: PMC6707837.. PubMed PMID: 31170413; PMCID: PMC6707837.
. Activation of Pregnane X Receptor Sensitizes Mice to Hemorrhagic Shock-Induced Liver Injury. Hepatology. 2019-09-01;70(3):995-1010. doi: 10.1002/hep.30691. nihFormattedCitation: Xie Y, Xu M, Deng M, Li Z, Wang P, Ren S, Guo Y, Ma X, Fan J, Billiar TR, Xie W. Activation of Pregnane X Receptor Sensitizes Mice to Hemorrhagic Shock-Induced Liver Injury. Hepatology. 2019;70(3):995-1010. PMCID: PMC6717545.. PubMed PMID: 31038762; PMCID: PMC6717545.
. Artificial intelligence-directed prognostication of breast cancer. EBioMedicine. 2019-08-01;466-7. doi: 10.1016/j.ebiom.2019.07.073. nihFormattedCitation: Nasrazadani A, Brufsky AM. Artificial intelligence-directed prognostication of breast cancer. EBioMedicine. 2019;46:6-7. PMCID: PMC6712046.. PubMed PMID: 31378696; PMCID: PMC6712046.
. Multicenter study demonstrates radiomic features derived from magnetic resonance perfusion images identify pseudoprogression in glioblastoma. Nat Commun. 2019-07-18;10(1):3170. doi: 10.1038/s41467-019-11007-0. nihFormattedCitation: Elshafeey N, Kotrotsou A, Hassan A, Elshafei N, Hassan I, Ahmed S, Abrol S, Agarwal A, El Salek K, Bergamaschi S, Acharya J, Moron FE, Law M, Fuller GN, Huse JT, Zinn PO, Colen RR. Multicenter study demonstrates radiomic features derived from magnetic resonance perfusion images identify pseudoprogression in glioblastoma. Nat Commun. 2019;10(1):3170. PMCID: PMC6639324.. PubMed PMID: 31320621; PMCID: PMC6639324.
. Creatine based polymer for codelivery of bioengineered MicroRNA and chemodrugs against breast cancer lung metastasis. Biomaterials. 2019-07-01;21025-40. doi: 10.1016/j.biomaterials.2019.04.025. nihFormattedCitation: Xu J, Sun J, Ho PY, Luo Z, Ma W, Zhao W, Rathod SB, Fernandez CA, Venkataramanan R, Xie W, Yu AM, Li S. Creatine based polymer for codelivery of bioengineered MicroRNA and chemodrugs against breast cancer lung metastasis. Biomaterials. 2019;210:25-40. PMCID: PMC6538300.. PubMed PMID: 31054369; PMCID: PMC6538300.
. Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers. Gastroenterology. 2019-06-01;156(8):2242-2253.e4. doi: 10.1053/j.gastro.2019.02.037. nihFormattedCitation: Singhi AD, George B, Greenbowe JR, Chung J, Suh J, Maitra A, Klempner SJ, Hendifar A, Milind JM, Golan T, Brand RE, Zureikat AH, Roy S, Schrock AB, Miller VA, Ross JS, Ali SM, Bahary N. Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers. Gastroenterology. 2019;156(8):2242-2253.e4.. PubMed PMID: 30836094.
. Predicting Outcome in Head and Neck Cancer: miRNAs with Potentially Big Effects. Clin Cancer Res. 2019-03-01;25(5):1441-1442. doi: 10.1158/1078-0432.CCR-18-3078. nihFormattedCitation: Clump DA, Pickering CR, Skinner HD. Predicting Outcome in Head and Neck Cancer: miRNAs with Potentially Big Effects. Clin Cancer Res. 2019;25(5):1441-1442. PMCID: PMC6415532.. PubMed PMID: 30413524; PMCID: PMC6415532.
. Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance. J Immunother Cancer. 2018-12-04;6(1):137. doi: 10.1186/s40425-018-0460-5. nihFormattedCitation: Boyiadzis MM, Dhodapkar MV, Brentjens RJ, Kochenderfer JN, Neelapu SS, Maus MV, Porter DL, Maloney DG, Grupp SA, Mackall CL, June CH, Bishop MR. Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance. J Immunother Cancer. 2018;6(1):137. PMCID: PMC6278156.. PubMed PMID: 30514386; PMCID: PMC6278156.
. Metformin action through the microbiome and bile acids. Nat Med. 2018-12-01;24(12):1789-1790. doi: 10.1038/s41591-018-0273-6. nihFormattedCitation: Guo GL, Xie W. Metformin action through the microbiome and bile acids. Nat Med. 2018;24(12):1789-1790.. PubMed PMID: 30523325.
. Novel glucosylceramide synthase inhibitor based prodrug copolymer micelles for delivery of anticancer agents. J Control Release. 2018-10-28;288212-226. doi: 10.1016/j.jconrel.2018.09.011. nihFormattedCitation: Xu J, Zhao W, Sun J, Huang Y, Wang P, Venkataramanan R, Yang D, Ma X, Rana A, Li S. Novel glucosylceramide synthase inhibitor based prodrug copolymer micelles for delivery of anticancer agents. J Control Release. 2018;288:212-226. PMCID: PMC6177216.. PubMed PMID: 30223045; PMCID: PMC6177216.
. Disease Response with the Addition of Platinum-Based Chemotherapy to Pembrolizumab after Progression on Pembrolizumab Monotherapy in PD-L1-Expressing Non-Small Cell Lung Cancer. J Thorac Oncol. 2018-08-01;13(8):e135-e136. doi: 10.1016/j.jtho.2018.02.031. nihFormattedCitation: Garcia CA, Dacic S, Villaruz LC. Disease Response with the Addition of Platinum-Based Chemotherapy to Pembrolizumab after Progression on Pembrolizumab Monotherapy in PD-L1-Expressing Non-Small Cell Lung Cancer. J Thorac Oncol. 2018;13(8):e135-e136.. PubMed PMID: 30049372.
